

Modus Therapeutics Presents Preclinical Data Supporting Sevuparin's Effects in Chronic Kidney Disease at Biolron 2025

STOCKHOLM, SWEDEN – April 1, 2025: Modus Therapeutics Holding AB (“Modus”), a company developing innovative treatments for patients with significant unmet medical needs, today announced that preclinical data on its proprietary clinical candidate sevuparin will be presented at the upcoming 10th Congress of the Biolron Society, to be held on May 25–29 in Montreal, Canada.

The oral presentation, titled “*The Heparinoid Sevuparin Improves Anemia and Kidney Status in a Mouse Model of Chronic Kidney Disease*,” will be delivered on May 27 by Dr. Michela Asperti, senior researcher in Professor Maura Poli’s team at the University of Brescia. The study demonstrates that sevuparin improves anemia and kidney status in a well-established chronic kidney disease (CKD) mouse model.

“We are truly grateful for our longstanding and productive collaboration with Professor Poli and her team, who continue to lead important research in iron regulation and anemia,” said John Öhd, CEO of Modus Therapeutics.

In the presented data, treatment with sevuparin alone in this mouse model resulted in improved hemoglobin levels and suppression of hepcidin – the key regulator of iron metabolism. When administered in combination with erythropoietin (EPO), the standard of care for CKD-related anemia, sevuparin enhanced and sustained the hemoglobin response over a six-week period. Furthermore, positive changes of the treatment on renal status were demonstrated through lowered levels of creatinine and reduced tissue fibrosis.

“These data, along with our previously published results in *HemaSphere* (December 2024), underscore sevuparin’s therapeutic potential in anemia associated with kidney disease, chronic inflammation and the regulation of hepcidin,” Öhd continued. “They form an important part of the scientific basis for our ongoing Phase II study in patients with CKD and anemia.”

The program for the Biolron Congress is available through this link: <https://bioiron.org/docs/meetings/bio2505/schedule.aspx>

For more information on Modus Therapeutics, please contact:

John Öhd, CEO, Modus Therapeutics

Phone: +46 (0) 70 766 80 97

Email: john.ohd@modustx.com

Certified Adviser

Svensk Kapitalmarknadsgranskning AB
Website: www.skmg.se

About Modus Therapeutics and sevuparin

Modus is a Swedish biotechnology company that is developing its proprietary polysaccharide sevuparin as a potential treatment for several major healthcare needs including sepsis, endotoxemia, severe malaria and other disorders with severe systemic inflammation as well as states of anemia, related to chronic inflammation such as kidney disease. There is a great need for new treatments that can effectively treat these conditions. Modus' ambition is to create a paradigm shift in the care of these diseases, where sevuparin could provide therapeutic benefits. Modus Therapeutics is listed on the Nasdaq First North Growth market ("MODTX"). More information is available at www.modustx.com.

Sevuparin is a clinical stage, innovative proprietary polysaccharide drug with a multimodal mechanism of action, including immunomodulating, anti-adhesive and anti-aggregate effects. Sevuparin is a heparinoid with markedly attenuated anti-coagulation features that allows severalfold higher doses to be given, compared to regular heparinoids, without the associated risk for bleeding side-effects. Two routes of administration of sevuparin are currently being tested – an IV formulation for in-patient administration and a subcutaneous formulation that allows ambulatory and home care administration.

Attachments

[Modus Therapeutics Presents Preclinical Data Supporting Sevuparin's Effects in Chronic Kidney Disease at Biolron 2025](#)